A new study carried out by a team of doctors has proved that Ivabradine drug can help reduce the deaths caused by heart failure to a great extent. It is estimated that heart failure affects 900,000 people in UK, causing 100,000 deaths a year. However, the results of this drug are estimated to decline the death rate by more than a third.
Professor Martin Cowie, Consultant Cardiologist at the Royal Brompton Hospital in London who led this study, carried out a clinical trial ‘Shift’ before effusing the life saving statements. The clinical trials carried out on the drug showed that it abates the possibilities of death from heart failure by 39% and thus cutting the rate of hospital admissions by 24%.
A case that was considered while clinical trials added to the success story of this drug. Anne Tanner, who was diagnosed with heart failure in 2007, was put on this drug as part of her medication. The treatment has changed her life completely. She states that she is able to perform all the activities that she was unable to carry out before the treatment.
The main causes that doctors analyze in case of heart failure are articulated to be heart attack, that weaken the heart and due to this the pumping system is also damaged. As a result, there is a less supply of blood and thus oxygen to the heart. This drug further, acts by slowing down the heart beat. This action in turn helps the heart to pump oxygenated blood more efficiently. This drug is already used to treat angina.
The European Medicine Regulator, after beholding the consequences of the drug has approved its use for patients dealing with heart failure. This drug will be launched at a price rate that will cost no more than £1.50 a day, thus costing less than £10 a week.
- J. Michael Pearson, Valeant’s Chief Executive Officer Spent Christmas in Hospital for ‘Severe’ Pneumonia
- Eversource Faces Stiff Challenge from ‘Society for the Protection of New Hampshire Forests’ over Burying Power Lines
- Shaw Communications Agree to Buy Wind Mobile for C$1.6 Billion
- Supporters of The Export-Import Bank in Congress make an Attempt to Revive It